BioCentury | May 17, 2019
Financial News

Actuate gets $21.7M to expand clinical testing of lead candidate

...of its GSK3B inhibitor into Europe and advance its pediatric neuroblastoma program for the candidate. Kairos...
BioCentury | Apr 27, 2018
Company News

Mammoth emerges to bring CRISPR into diagnostic space

...in multiple settings. Mammoth has raised undisclosed funds from Mayfield, NFX, 8VC, AME Cloud, Wireframe, Kairos...
BioCentury | Apr 26, 2018
Company News

Mammoth emerges, among first diagnostic-focused CRISPR companies

...in multiple settings. Mammoth has raised undisclosed funds from Mayfield, NFX, 8VC, AME Cloud, Wireframe, Kairos...
BioCentury | Apr 26, 2018
Emerging Company Profile

Mammoth makes Dx CRISPR

...of employees: 5 Funds raised: Undisclosed Investors: Mayfield, NFX, 8VC, AME Cloud Ventures, Wireframe Ventures, Kairos...
BioCentury | Aug 17, 2017
Finance

Built to purpose

...Pharmaceuticals Inc. Novartis AG (NYSE:NVS; SIX:NOVN) MPM Capital Hematology Single asset $32 $300 2013 undisclosed Kairos...
BioCentury | Mar 23, 2017
Financial News

Neuro-Bio completes venture financing

...disease company Neuro-Bio Ltd. (Abingdon, U.K.) raised $3.2 million in a series A round from Kairos...
BioCentury | Dec 2, 2016
Finance

Bug-brain axis

...a $19.2 million series A co-led by Longwood Fund and Domain Associates and joined by Kairos...
BioCentury | Dec 1, 2016
Financial News

Axial Biotherapeutics completes venture financing

...raised $19.2 million in a series A round led by Longwood Fund and Domain Associates. Kairos...
BioCentury | Nov 30, 2016
Financial News

Microbiome newco Axial raises $19.2M

...to develop microbiome-based treatments for CNS disorders. Longwood Fund and Domain Associates co-led the round. Kairos...
BioCentury | Oct 20, 2016
Finance

3Q16 Public-Private Partnership Roundup

...bladder cancer therapeutic delivered via nanoparticles - into clinical trials. March 2016 Kairos Therapeutics Inc. Kairos...
Items per page:
1 - 10 of 14
BioCentury | May 17, 2019
Financial News

Actuate gets $21.7M to expand clinical testing of lead candidate

...of its GSK3B inhibitor into Europe and advance its pediatric neuroblastoma program for the candidate. Kairos...
BioCentury | Apr 27, 2018
Company News

Mammoth emerges to bring CRISPR into diagnostic space

...in multiple settings. Mammoth has raised undisclosed funds from Mayfield, NFX, 8VC, AME Cloud, Wireframe, Kairos...
BioCentury | Apr 26, 2018
Company News

Mammoth emerges, among first diagnostic-focused CRISPR companies

...in multiple settings. Mammoth has raised undisclosed funds from Mayfield, NFX, 8VC, AME Cloud, Wireframe, Kairos...
BioCentury | Apr 26, 2018
Emerging Company Profile

Mammoth makes Dx CRISPR

...of employees: 5 Funds raised: Undisclosed Investors: Mayfield, NFX, 8VC, AME Cloud Ventures, Wireframe Ventures, Kairos...
BioCentury | Aug 17, 2017
Finance

Built to purpose

...Pharmaceuticals Inc. Novartis AG (NYSE:NVS; SIX:NOVN) MPM Capital Hematology Single asset $32 $300 2013 undisclosed Kairos...
BioCentury | Mar 23, 2017
Financial News

Neuro-Bio completes venture financing

...disease company Neuro-Bio Ltd. (Abingdon, U.K.) raised $3.2 million in a series A round from Kairos...
BioCentury | Dec 2, 2016
Finance

Bug-brain axis

...a $19.2 million series A co-led by Longwood Fund and Domain Associates and joined by Kairos...
BioCentury | Dec 1, 2016
Financial News

Axial Biotherapeutics completes venture financing

...raised $19.2 million in a series A round led by Longwood Fund and Domain Associates. Kairos...
BioCentury | Nov 30, 2016
Financial News

Microbiome newco Axial raises $19.2M

...to develop microbiome-based treatments for CNS disorders. Longwood Fund and Domain Associates co-led the round. Kairos...
BioCentury | Oct 20, 2016
Finance

3Q16 Public-Private Partnership Roundup

...bladder cancer therapeutic delivered via nanoparticles - into clinical trials. March 2016 Kairos Therapeutics Inc. Kairos...
Items per page:
1 - 10 of 14